Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: Response to therapy is linked to the duration of progressive disease

Multiple Sclerosis

Volumn 5, Issue 6, 1999, Pages 403-409

  Hohol, Marika J ^a   Olek, Michael J ^a   Orav, E John ^a   Stazzone, Lynn ^a   Hafler, David A ^a   Khoury, Samia J ^a   Dawson, David M ^a   Weiner, Howard L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cyclophosphamide; Immunosuppression; Multiple sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ADULT; ALLERGIC REACTION; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL PROTOCOL; DISEASE COURSE; DISEASE DURATION; FATIGUE; FEMALE; HEMATURIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUTROPENIA; ONSET AGE; OSTEOPOROSIS; OUTPATIENT CARE; TIME; TREATMENT OUTCOME; VOMITING;

EID: 0033391669     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245899678846492     Document Type: Article

References (49)

1. Martin R et al. (1992) Immunological aspects of demyelinatmg diseases. Ann Rev Immunol 10: 153-187.
2. Weiner HL et al. (1995) Therapy for MS. Neurologic Clinics 13: 173-196.
3. Jacobs LD et al. (1996) Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39: 285-294.
4. The IFNB MS Study Group and UBC MS/MRI Analysis Group. (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45: 1277-1285.
5. Johnson KP et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45: 1268-1276.
6. Goodkin DE et al. (1995) Low dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 37: 30-40.
7. Beutler E et al. (1996) The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 93: 1716-1720.
8. Anderson O et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47: 895-900.
9. Karussis DM et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47: 341-346.
10. Cook SD et al. (1987) Total lymphoid irradiation in multiple sclerosis. Blood lymphocytes and clinical course. Ann Neurol 22: 634-638.
11. Edan G et al. (1997) Therapeutic effect of mitoxanthrone combined with methylprednisolone in multiple sclerosis: a randomized multicenter study of active disease using MRI and clinical criteria. J Neurol Psychiatr 62: 112-118.
12. Noseworthy JH et al. (1998) The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 51: 1342-1352.
13. European Study Group on Interferon β-1b in Secondary Progressive MS. (1998) Placebo-controlled multicentre randomised trial of Interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352: 1491-1497.
14. Aimard G et al. (1966) Sclerose en plaques et processus d'autoimmunisation. Traitment par les anti-mitotiques. Lyon Med 215: 345-352.
15. Hommes OR et al. (1975) Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clinical Neurology and Neurosurgery 78: 59-73.
16. Gonsette R et al. (1977) Intensive immunosuppression with cyclophosphamide in multiple sclerosis: follow-up of 110 patients for 2-6 years. J Neuroimmunol 214: 173-181.
17. Hommes OR et al. (1980) Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol 223: 177-190.
18. Hommes OR et al. (1980) Prognostic factors in intensive immunosuppression on the course of chronic progressive multiple sclerosis. In: Progress in multiple sclerosis research. Bauer HJ, Poser S, Ritter G (eds) Berlin: Springer Verlag, pp. 396-400.
19. Hauser SL et al. (1983) Intensive immunosuppression in progressive multiple sclerosis: A randomized, three-arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 308: 173-180.
20. Carter JL et al. (1988) Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis; cumulative 6-year experience in 164 patients. Neurology 38: 9-14.
21. Myers LW et al. (1987) Cyclophosphamide 'pulses' in chronic progressive multiple sclerosis. Arch Neurol 44: 828-832.
22. Mickey MR et al. (1987) Correlation of clinical and immunological states in multiple sclerosis. Arch Neurol 44: 371-375.
23. Goodkin DE et al. (1987) Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs. nonmaintenance therapy. Arch Neurol 44: 823-827.
24. Killian JM et al. (1988) Controlled pilot trial on monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol 45: 27-30.
25. Mauch E et al. (1989) Effective treatment of chronic progressive multiple sclerosis with low-dose cyclophosphamide with minor side-effects. Eur Arch Psych Neurol Sci 238: 115-117.
26. Trouillas P et al. (1989) Immunosuppression intensive dans la sclerose en plaques progressive etude ouverte comparant trois groupes: cyclophosphamide, cyclophosphamide-plasmaphereses et temoins resultats a trois ans. Rev Neurol 145: 369-377.
27. Likosky WH et al. (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatr 54: 1055-1060.
28. The Canadian Cooperative Multiple Sclerosis Study Group. (1991) The Canadian Cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337: 442-446.
29. Weinstock-Guttmann B et al. (1997) Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. The Neurologist 3: 178-185.
30. Hafler DA et al. (1991) Immunologic effects of cyclophosphamide/ACTH in patient with chronic progressive multiple sclerosis. J Neuroimmunol 32: 149-158.
31. Hohol MJ et al. (1992) Pilot study of three year intermittent pulse cyclophosphamide/methylprednisolone therapy in multiple sclerosis (abstract). Ann Neurol 32: 256-257.
32. Weiner HL et al. (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report on the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43: 910-918.
33. Smith D et al. (1997) Immune deviation following cyclophosphamide/methylprednisolone treatment of multiple sclerosis; Increased IL-4 and associated eosinophilia. Ann Neurol 42: 313-318.
34. Takashima H et al. (1998) Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4 secreting T cells in multiple sclerosis patients. Clin Immunol Immunopathol 88: 28-34.
35. Cornabella M et al. (1998) Elevated interleuken-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 102: 671-678.
36. McCune W et al. (1988) Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in lupus erythematosis. N Engl J Med 318: 1423-1431.
37. Gourley M et al. (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized controlled trial. Ann Int Med 125: 549-557.
38. Goodkin DE et al. (1998) A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51: 239-245.
39. Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444-1452.
40. Lublin FD et al. (1996) Defining the clinical course of multiple sclerosis; results on an international survey. Neurology 46: 907-911.
41. Weinshenker BG, Issa M, Baskerville J. (1996) Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 46: 1613-1619.
42. Noseworthy JH et al. (1993) An open-trial evaluation of mitoxanthrone in the treatment of progressive MS. Neurology 43: 1401-1406.
43. Bornstein MB et al. (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41: 533-539.
44. Kidd D et al. (1996) MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatr 60: 15-19.
45. Balashov KE et al. (1997) Increased IL-12 production in progressive multiple sclerosis: Induction by activated CD4+ cells via CD40 ligand. Proc Natl Acad Sci USA 94: 599-603.
46. Hafler DA et al. (1985) In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med 312: 1405-1411.
47. Karp C. (1999) Interleukin-12: Amiss in MS. Ann Neurol 45: 689-692.
48. Van Boxel-Dezaire, AHH et al. (1999) Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different stages in multiple sclerosis. Ann Neurol 45: 695-703.
49. Gobbini MI et al 1999. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 99: 142-149.